Researchers claim vitamin supplements and new technology can help prevent secondary stroke medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
The phase 3 OCEANIC-AF trial of the factor XI inhibitor asundexian (Bayer) has been stopped early owing to inferior efficacy vs apixaban in preventing stroke and systemic embolism in patients with AF.
Mobile stroke units equipped with clot busting medications, CT machines, and video connections to a physician are linked to better patient outcomes, including stroke avoidance, vs traditional EMS.
The anti-inflammatory agent, started within 24 hours of acute ischemic stroke or TIA, did not reduce subsequent stroke or other vascular events at 90 days in the CHANCE-3 trial.
Program participants at Stroke Comeback Center pose for a group photo. Participants include survivors of all ages and backgrounds. (Photo: Stroke Comeback C .